Proteros Biostructures GmbH is a leading Germany-based founder-led contract research organisation focused on early-stage drug discovery. Inflexion’s dedicated minority investment fund, Partnership Capital II made the investment in 2023.

  • Sector


  • Headquarters

    Munich, Germany

  • Fund

    Partnership Capital

  • Investment date

    January 2023

  • Status


The company

Proteros is a specialist in structural biology which has created a cutting-edge platform recognised globally by both large pharma and biotechs as capable of unlocking the most technically challenging drug targets. Munich-based Proteros supports many of the world’s top 20 largest pharmaceutical companies and over 200 pharma and biotech partners in the US, Europe and Japan to reach the right results and accelerate their overall research timelines, helping them to lead optimisation and clinical programmes.

The firm was founded in 2000 by Dr Torsten Neuefeind (CEO) and Nobel Laureate Prof. R Huber, and today it boasts leading technologies that enable users to map the shape of a drug target with a high degree of precision.

The Inflexion difference

Working closely with the Founder and CEO, Inflexion is supporting Proteros to scale globally both organically and through acquisition, particularly in the US. Inflexion’s proven history and expertise in healthcare, technology and commercial strategy will further strengthen Proteros’ overall value proposition for its blue-chip customer base.


Press releases